The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Aromatase Inhibitors for Breast Cancer Prevention
Abstract
Many lines of evidence point to sex hormones as the key factors in breast carcinogenesis. Classic risk factors include age at menarche, first child birth, and menopause. Estrogens, especially estradiol, appear to be the main factor. Hormone replacement therapy increases breast cancer risk, especially when the combined pills using estrogen and progesterone are used. Weight is a risk factor for postmenopausal breast cancer,wherearomatizationofandrogens inadipose tissue is the major source of estrogen. The variability of serum oestrogen levels in postmenopausal women from the lowest to highest quintile (about a six-fold difference) is associated with a two-fold variation in breast cancer risk (Fig 1). Estrogen appears to be more closely linked with breast cancer than are the other steroid sex hormones, although theymay alsohave an independent role. Lastly, fourmajor trials using the estrogen agonist, tamoxifen, to block the activity of estrogen at the receptor have shown that about 50% of estrogen receptor (ER) -positive breast cancers (Fig 2A) can be prevented, although there appears to be little effect on ER-negative breast cancer (Fig 2B), leading to a 38% overall reduction in breast cancer. Although the use of tamoxifen has been effective in reducing the incidence of breast cancer, both in the contralateral breast for women with early breast cancer, and for those at high risk who have not had the disease, it is not without side effects, especially thromboembolic events and gynecologic symptoms, and this limits its utility in a prevention setting. Recently, the third-generation aromatase inhibitors (AIs) have been introduced into the treatment of breast cancer, and their greater efficacy compared to tamoxifen, along with a more favorable side-effect profile, make them attractive agents for use in breast cancer prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Buzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2000 · Cited by 406
Cited by
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Cuzick, J., Sestak, I., Forbes, J. F., Dowsett, M., Knox, J., Cawthorn, S., Saunders, C., Roche, N., Mansel, R. E., von Minckwitz, G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62292-8 · Cited by 590
Self-citationKauff, N. D., Domchek, S. M., Friebel, T. M., Robson, M. E., Lee, J., Garber, J. E., Isaacs, C., Evans, D. G., Lynch, H., Eeles, R. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9626 · Cited by 589
Cuzick, J., Forbes, J. F., Sestak, I., Cawthorn, S., Hamed, H., Holli, K., & Howell, A. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk049 · Cited by 534
Self-citationPersonalized early detection and prevention of breast cancer: ENVISION consensus statement
Pashayan, N., Antoniou, A. C., Ivanus, U., Esserman, L. J., Easton, D. F., French, D., Sroczynski, G., Hall, P., Cuzick, J., Evans, D. G., et al. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0388-9 · Cited by 438
Self-citation
Metadata
- Authors
- Cuzick, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-03-10
- Volume
- 23
- Issue
- 8
- Pages
- 1636-1643
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2134113023
- Cited by
- 161
- References
- 2
- FWCI
- 12.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aromatase Inhibitors for Breast Cancer Prevention. https://app.cochat.ai/papers/10.1200/jco.2005.11.027
- The paper
- Cuzick, J. (2005). Aromatase Inhibitors for Breast Cancer Prevention. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.11.027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.